Second neoplasms after treatment of childhood cancer in Slovenia

Jazbec, Janez; Ecimovic, P.; Jereb, Berta

doi:10.1002/pbc.20025

Cited by 28 publications

(24 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously noted, the radiation treatment related risks of thyroid cancer can be more commonly seen among survivors of leukemia and lymphoma [3]. On the other hand, even in lymphoma survivors not treated with external radiotherapy a significant increased risk of developing thyroid cancer has been defined possibly due to immune dysfunction or related factors [3]. In our patients, tumor histology was usually papillary carcinoma in previously irradiated patients and regional lymph node involvement was more frequent in agreement with previous reports [4,5].…”

Section: Discussionsupporting

confidence: 91%

“…Moreover, in agreement with these observations mostly observed primary neoplasms in group I patients were lymphoma and leukemia followed by breast and CNS neoplasms. As previously noted, the radiation treatment related risks of thyroid cancer can be more commonly seen among survivors of leukemia and lymphoma [3]. On the other hand, even in lymphoma survivors not treated with external radiotherapy a significant increased risk of developing thyroid cancer has been defined possibly due to immune dysfunction or related factors [3].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multiple Primary Tumors in Differentiated Thyroid Carcinoma and Relationship to Thyroid Cancer Outcome

et al. 2008

View full text Add to dashboard Cite

Abstract. AIM: Patients with differentiated thyroid carcinoma (DTC) have long-life expectancy and are at risk for developing a second primary cancer. Aim of this study was to assess the occurrence of DTC in conjunction with other primary neoplasms. It was also aimed to explore the possibility of synchronous or metachronous other malignancies having an impact on clinical course of thyroid carcinoma. MATERIAL & METHODS: Clinical records of 1680 DTC patients treated and followed in our institution over last twenty years were reviewed. Forty-five second primary tumors were found in 42 patients. These patients were classified into 3 groups as antecedent (group I), synchronous (group II) or subsequent (group III) according to the timing of occurrence of non-thyroidal malignancy. The initial characteristics of thyroid neoplasm were compared between patients with DTC plus another tumor and DTC only. Kaplan-Meier Survival Analysis was used to estimate the survival probability for patients with DTC alone and DTC plus another primary tumor. RESULTS: There were 15 synchronous and 30 metachronous tumors in 42 patients. Three of them had triple tumors. The most common second primary was lympho-haematological and upper aero digestive system tumors in group I and II respectively, whereas a variety of tumors were noted in group III. Despite the more common occurrence of unfavourable prognostic factors in patients with multiple cancers than thyroid cancer alone, complete response to radioiodine therapy and recurrence free survival rate was similar in both groups (p>0.05). CONCLUSION: The results of the current series imply that the occurrence of multiple primary tumors is not uncommon in patients with DTC. Close medical surveillance and the use of advanced screening modalities might lead to the detection of second primary tumors in DTC. However, the presence of second primary seems not to affect the clinical course of DTC.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Multiple Primary Tumors in Differentiated Thyroid Carcinoma and Relationship to Thyroid Cancer Outcome

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Unlike the retrospective cohort CCSS, our studies only prospectively followed GH-treated patients. Additionally, the duration of follow-up was much longer in the CCSS and the incidence of SN is known to increase with longer periods of observation (27).…”

Section: Discussionmentioning

confidence: 99%

Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS

Woodmansee

Zimmermann

Child³

et al. 2013

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Childhood cancer survivors are commonly treated with GH for GH deficiency that develops either as a result of primary malignancy or its treatment. One study -the Childhood Cancer Survivor Study (CCSS) -demonstrated increased risk of second neoplasm (SN) in GH-treated childhood cancer survivors compared with non-GH treated, after adjusting for key risk factors. We assessed the incidence of SN in GH-treated childhood cancer survivors in outpatient observational studies of GH replacement. Design: Retrospective analysis of two prospective cohort studies that collected data on safety of GH replacement as prescribed in clinical practice. Methods: Childhood cancer survivors enrolled in Eli Lilly and Company's pediatric (Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS)) and adult (Hypopituitary Control and Complications Study (HypoCCS)) observational studies of GH treatment were assessed for incidence of SN. Results: The percentage of childhood cancer survivors treated with GH who developed a SN was 3.8% in pediatric GeNeSIS participants and 6.0% in adult HypoCCS participants. The estimated cumulative incidence of SN at 5 years of follow-up in these studies was 6.2 and 4.8% respectively. Conclusions: The incidence of SN in GeNeSIS and HypoCCS GH-treated participants is similar to the published literature and is thus consistent with increased risk of SN in childhood cancer survivors treated with GH. As follow-up times were relatively short (!3 years), longer observation is recommended. Nevertheless, clinicians should be alerted to the possibility of increased risk of SN in childhood cancer survivors treated with GH and continue chronic surveillance.

show abstract

“…In general the estimation of risk varies, between hospital based and population based studies [2], probably due to more complete follow-up in the former registries. Our population based study, differs from similar studies also for defining a period at risk for SMN, from the diagnosis of primary cancer on.…”

Section: Discussionmentioning

confidence: 99%

“…Relevant reports of the cumulative probability of developing SN vary from 3.3% to 25% at 25 years from diagnosis. Thus, the risk of developing another cancer can be up to 35 times greater than in the general population [2].…”

Section: Introductionmentioning

confidence: 99%

Classification tree analysis of second neoplasms in survivors of childhood cancer

2007

Self Cite

View full text Add to dashboard Cite

show abstract

Second neoplasms after treatment of childhood cancer in Slovenia

Abstract: Patients after treatment of childhood cancer are at special risk for subsequent neoplasms and long-term follow-up is mandatory.

Cited by 28 publications

References 29 publications

Multiple Primary Tumors in Differentiated Thyroid Carcinoma and Relationship to Thyroid Cancer Outcome

Multiple Primary Tumors in Differentiated Thyroid Carcinoma and Relationship to Thyroid Cancer Outcome

Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS

Classification tree analysis of second neoplasms in survivors of childhood cancer

Contact Info

Product

Resources

About